Entera Bio (ENTX) Net Income towards Common Stockholders (2021 - 2026)
Entera Bio (ENTX) recorded quarterly Net Income towards Common Stockholders of -$3.5 million in Q1 2026, down 16.84% on a QoQ basis from -$3.0 million in Q4 2025, and down 38.08% year-over-year from -$5.7 million in Q1 2025.
Entera Bio (ENTX) Net Income towards Common Stockholders (2021 - 2026) Analysis & Trends
Entera Bio has disclosed Net Income towards Common Stockholders across 6 years of filings, most recently posting -$3.5 million for Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 38.08% year-over-year to -$3.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$12.6 million (down 23.92% YoY) and the FY2025 annual result came in at -$11.4 million, down 19.89% from the prior year.
- Net Income towards Common Stockholders slipped to -$3.5 million in Q1 2026, from -$3.0 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at -$2.0 million in Q4 2023 and troughed at -$3.8 million in Q1 2022.
- A 5-year average of -$2.7 million and a median of -$2.7 million in 2025 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders slumped 64.81% — and 2023, when it soared 42.12%.
- Tracing ENTX's Net Income towards Common Stockholders over 5 years: stood at -$3.0 million in 2022, then jumped by 34.27% to -$2.0 million in 2023, then slipped by 18.2% to -$2.4 million in 2024, then fell by 28.46% to -$3.0 million in 2025, then decreased by 16.84% to -$3.5 million in 2026.
- Business Quant data shows ENTX's Net Income towards Common Stockholders at -$3.5 million in Q1 2026, -$3.0 million in Q4 2025, and -$3.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -3.63 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -56.48 Mn |
| 10 | Entera Bio | 56.59 Mn | 52.45 Mn | - | -3.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.54 Mn |
| Dec 31, 2025 | -3.03 Mn |
| Sep 30, 2025 | -3.30 Mn |
| Jun 30, 2025 | -2.70 Mn |
| Mar 31, 2025 | -2.56 Mn |
| Dec 31, 2024 | -2.36 Mn |
| Sep 30, 2024 | -3.02 Mn |
| Jun 30, 2024 | -2.20 Mn |
| Mar 31, 2024 | -2.06 Mn |
| Dec 31, 2023 | -2.00 Mn |
| Sep 30, 2023 | -2.38 Mn |
| Jun 30, 2023 | -2.33 Mn |
| Mar 31, 2023 | -2.19 Mn |
| Dec 31, 2022 | -3.04 Mn |
| Sep 30, 2022 | -3.07 Mn |
| Jun 30, 2022 | -3.19 Mn |
| Mar 31, 2022 | -3.78 Mn |
| Dec 31, 2021 | -4.10 Mn |
| Sep 30, 2021 | -3.21 Mn |
| Jun 30, 2021 | -2.58 Mn |